FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation

Nature Reviews Cancer

Volumn 8, Issue 2, 2008, Pages 83-93

  Welcker, Markus ^a   Clurman, Bruce E ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN E; NOTCH RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; UBIQUITIN PROTEIN LIGASE;

BLADDER CANCER; BREAST CANCER; BURKITT LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; DIMERIZATION; DROSOPHILA MELANOGASTER; ENDOMETRIUM CANCER; FBW7 GENE; GENE; GENE MUTATION; HUMAN; LIVER CANCER; NONHUMAN; ONCOGENE MYC; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTO ONCOGENE; REVIEW;

ANIMALS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CYCLIN E; DIMERIZATION; F-BOX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 38549086019     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2290     Document Type: Review

References (119)

1. Hershko, A. Ubiquitin: roles in protein modification and breakdown. Cell 34, 11-12 (1983).
2. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. Cancer 6, 369-381 (2006). An excellent up-to-date review of SCF and APC/C ubiquitin ligases.
3. Hartwell, L. H., Mortimer, R. K., Culotti, J. & Culotti, M. Genetic control of the cell division cycle in yeast: V. genetic analysis of cdc mutants. Genetics 74, 267-286 (1973).
4. Schwob, E., Bohm, T., Mendenhall, M. D. & Nasmyth, K. The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae. Cell 79, 233-244 (1994).
5. Verma, R. et al. Phosphorylation of Sic1p by G1 Cdk required for its degradation and entry into S phase. Science 278, 455-460 (1997).
6. Verma, R., Feldman, R. M. & Deshaies, R. J. SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities. Mol. Biol. Cell 8, 1427-1437 (1997).
7. Skowyra, D., Craig, K. L., Tyers, M., Elledge, S. J. & Harper, J. W. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91, 209-219 (1997).
8. Feldman, R. M., Correll, C. C., Kaplan, K. B. & Deshaies, R. J. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91, 221-230 (1997). References 4-8 and 28 were instrumental for discovering the function of SCF ubiquitin ligases.
9. Henchoz, S. et al. Phosphorylation- and ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor Far1p in budding yeast. Genes Dev. 11, 3046-3060 (1997).
10. CDC4 ubiquitin-ligase complex. Mol. Biol. Cell 11, 915-927 (2000).
11. CDC4 recognition elements target Cdc6 for proteolysis in S phase and mitosis. EMBO J. 20, 4836-4845 (2001).
12. Drury, L. S., Perkins, G. & Diffley, J. F. The Cdc4/34/53 pathway targets Cdc6p for proteolysis in budding yeast. EMBO J. 16, 5966-5976 (1997).
13. Benito, J., Martin-Castellanos, C. & Moreno, S. Regulation of the G1 phase of the cell cycle by periodic stabilization and degradation of the p25rum1 CDK inhibitor. EMBO J. 17, 482-497 (1998).
14. Nash, P. et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414, 514-521 (2001). This paper defines the CPD.
15. Fbw7 ubiquitin ligase. Science 294, 173-177 (2001).
16. Sundaram, M. & Greenwald, I. Suppressors of a lin-12 hypomorph define genes that interact with both lin-12 and glp-1 in Caenorhabditis elegans. Genetics 135, 765-783 (1993).
17. Hubbard, E. J., Wu, G., Kitajewski, J. & Greenwald, I. sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev. 11, 3182-3193 (1997). References 16 and 17 identify Sel10/FBW7 as a Notch regulator in worms, and references 18-20 confirm that this pathway is also active in human cells.
18. Oberg, C. et al. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J. Biol. Chem. 276, 35847-35853 (2001).
19. Wu, G. et al. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol. Cell. Biol. 21, 7403-7415 (2001).
20. Gupta-Rossi, N. et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 276, 34371-34378 (2001).
21. Maruyama, S. et al. Characterization of a mouse gene (Fbxw6) that encodes a homologue of Caenorhabditis elegans SEL-10. Genomics 78, 214-222 (2001).
22. Moberg, K. H., Bell, D. W., Wahrer, D. C., Haber, D. A. & Hariharan, I. K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413, 311-316 (2001).
23. Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316-322 (2001). References 15, 22 and 23 identify FBW7 as a ubiquitin ligase for cyclin E and found that FBW7 is mutated in tumour cell lines (references 22 and 23) and downregulated in cancer (reference 15).
24. Spruck, C. H. et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62, 4535-4539 (2002).
25. Matsumoto, A., Onoyama, I. & Nakayama, K. I. Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem. Biophys. Res. Commun. 350, 114-119 (2006).
26. Kimura, T., Gotoh, M., Nakamura, Y. & Arakawa, H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94, 431-436 (2003).
27. Mao, J. H. et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432, 775-779 (2004). References 26 and 27 identify the FBW7β isoform as a p53-regulated transcript.
28. Bai, C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274 (1996).
29. Cdc4 ubiquitin ligase. Cell 112, 243-256 (2003).
30. Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. & Pavletich, N. P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131-143 (2007). References 29 and 30 provide crystal structures of yeast Cdc4 and human FBW7, respectively, and define the contacts made with CPDs.
31. Welcker, M. & Clurman, B. E. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2, 7 (2007).
32. Cdc4 dimer accommodates multiple geometries for substrate ubiquitination. Cell 129, 1165-1176 (2007).
33. Zhang, W. & Koepp, D. M. Fbw7 isoform interaction contributes to cyclin E proteolysis. Mol. Cancer Res. 4, 935-943 (2006).
34. Suzuki, H. et al. Homodimer of two F-box proteins βTrCP1 or βTrCP2 binds to IκBα for signal-dependent ubiquitination. J. Biol. Chem. 275, 2877-2884 (2000).
35. Welcker, M., Orian, A., Grim, J. E., Eisenman, R. N. & Clurman, B. E. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr. Biol. 14, 1852-1857 (2004).
36. Kominami, K., Ochotorena, I. & Toda, T. Two F-box/WD-repeat proteins Pop1 and Pop2 form hetero- and homo-complexes together with cullin-1 in the fission yeast SCF (Skp1-Cullin-1-F-box) ubiquitin ligase. Genes Cells 3, 721-735 (1998).
37. Koff, A. et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257, 1689-1694 (1992).
38. Dulic, V., Lees, E. & Reed, S. I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257, 1958-1961 (1992).
39. Hwang, H. C. & Clurman, B. E. Cyclin E in normal and neoplastic cell cycles. Oncogene 24, 2776-2786 (2005).
40. Geng, Y. et al. Kinase-independent function of cyclin E. Mol. Cell 25, 127-139 (2007).
41. Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M. & Roberts, J. M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10, 1979-1990 (1996).
42. Won, K. A. & Reed, S. I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15, 4182-4193 (1996).
43. Welcker, M. et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12, 381-392 (2003). This reference reports the identification of GSK3 as a CPD kinase and the identification of the + 4 negative charge in CPDs.
44. Fbw7 ubiquitin ligase. J. Biol. Chem. 279, 50110-50119 (2004).
45. Yeh, E. S., Lew, B. O. & Means, A. R. The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. J. Biol. Chem. 281, 241-251 (2006).
46. van Drogen, F. et al. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23, 37-48 (2006).
47. Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16, 653-99 (2000).
48. Amati, B. Myc degradation: dancing with ubiquitin ligases. Proc. Natl Acad. Sci. USA 101, 8843-8844 (2004).
49. Yada, M. et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23, 2116-2125 (2004).
50. Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085-9090 (2004).
51. Gomez-Roman, N. et al. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem. Soc. Symp. 73, 141-154 (2006).
52. Grandori, C. et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nature Cell Biol. 7, 311-318 (2005).
53. Popov, N. et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biol. 9, 765-774 (2007).
54. Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000).
55. Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biol. 6, 308-318 (2004).
56. Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nature Cell Biol. 4, 131-136 (2002).
57. Fbw7 antagonizes apoptotic JNK signaling. Science 303, 1374-1378 (2004).
58. Fuchs, S. Y. et al. c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J. Biol. Chem. 272, 32163-32168 (1997).
59. Musti, A. M., Treier, M. & Bohmann, D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275, 400-402 (1997).
60. Wei, W., Jin, J., Schlisio, S., Harper, J. W. & Kaelin, W. G., Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33 (2005).
61. Bengoechea-Alonso, M. T. & Ericsson, J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr. Opin. Cell Biol. 19, 215-222 (2007).
62. Fbw7. Cell Metab. 1, 379-391 (2005).
63. Punga, T., Bengoechea-Alonso, M. T. & Ericsson, J. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J. Biol. Chem. 281, 25278-25286 (2006).
64. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
65. Radtke, F., Schweisguth, F. & Pear, W. The Notch 'gospel'. EMBO Rep. 6, 1120-1125 (2005).
66. O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
67. FBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007). References 66, 67, 80 and 93 identified a clear preference for missense mutations in FBW7 in T-ALL, indicating that FBW7 mutants might have dominant-negative effects.
68. Klinakis, A. et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl Acad. Sci. USA 103, 9262-9267 (2006).
69. Weng, A. P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096-2109 (2006).
70. Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261-18266 (2006).
71. Sharma, V. M. et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol. Cell. Biol. 26, 8022-8031 (2006).
72. Wu, G., Hubbard, E. J., Kitajewski, J. K. & Greenwald, I. Evidence for functional and physical association between Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. Proc. Natl Acad. Sci. USA 95, 15787-15791 (1998).
73. Li, J. et al. SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-β peptide production. J. Neurochem. 82, 1540-1548 (2002).
74. Cohen, P. & Frame, S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2, 769-776 (2001).
75. Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204 (2004).
76. Tsunematsu, R. et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 279, 9417-9423 (2004).
77. Tetzlaff, M. T. et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl Acad. Sci. USA 101, 3338-3345 (2004).
78. Onoyama, I. et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 5 Nov 2007 (doi:10.1084/jem.20062299).
79. th Am. Soc. Hematol. Abstr. 79 (2006).
80. Knuutila, S. et al. DNA copy number losses in human neoplasms. Am. J. Pathol. 155, 683-694 (1999).
81. Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966-971 (2007).
82. Lee, J. W. et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur. J. Cancer 42, 2369-2373 (2006).
83. Kemp, Z. et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 65, 11361-11366 (2005).
84. Hubalek, M. M. et al. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 23, 4187-4192 (2004).
85. Koh, M. S., Ittmann, M., Kadmon, D., Thompson, T. C. & Leach, F. S. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol. Ther. 5, 78-83 (2006).
86. Calhoun, E. S. et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 163, 1255-1260 (2003).
87. Akhoondi, S. et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007). This paper documents an extensive genetic screen for mutations in FBW7 in over 1,500 diverse tumours.
88. Nowak, D. et al. Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism. Int. J. Med. Sci. 3, 148-151 (2006).
89. Woo Lee, J. et al. Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas. Acta Oncol. 45, 487-488 (2006).
90. Kwak, E. L. et al. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol. Oncol. 98, 124-128 (2005).
91. Sgambato, A. et al. Low frequency of hCDC4 mutations in human primary ovarian cancer. Gynecol. Oncol. 105, 553-555 (2007).
92. Yan, T. et al. hCDC4 variation in osteosarcoma. Cancer Genet. Cytogenet. 169, 138-142 (2006).
93. Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004). This paper shows that mutations in FBW7 can lead to genetic instability.
94. Malyukova, A. et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67, 5611-5616 (2007).
95. Papas, T. S. & Lautenberger, J. A. Sequence curiosity in v-myc oncogene. Nature 318, 237 (1985).
96. Maki, Y., Bos, T. J., Davis, C., Starbuck, M. & Vogt, P. K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl Acad. Sci. USA 84, 2848-2852 (1987).
97. Gregory, M. A. & Hann, S. R. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol. Cell. Biol. 20, 2423-2335 (2000).
98. Bahram, F., von der Lehr, N., Cetinkaya, C. & Larsson, L. G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95, 2104-2110 (2000).
99. Hemann, M. T. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807-811 (2005).
100. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
101. Hagedorn, M. et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 2, 9 (2007).
102. Gu, Z., Inomata, K., Ishizawa, K. & Horii, A. The FBXW7 β-form is suppressed in human glioma cells. Biochem. Biophys. Res. Commun. 354, 992-998 (2007).
103. Minella, A. C., Welcker, M. & Clurman, B. E. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc. Natl Acad. Sci. USA 102, 9649-54 (2005).
104. Welcker, M. & Clurman, B. E. The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J. Biol. Chem. 280, 7654-7658 (2005).
105. Bortner, D. M. & Rosenberg, M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17, 453-459 (1997).
106. Spruck, C. H., Won, K. A. & Reed, S. I. Deregulated cyclin E induces chromosome instability. Nature 401, 297-300 (1999).
107. Ekholm-Reed, S. et al. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res 64, 795-800 (2004).
108. Minella, A. C. et al. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr. Biol. 12, 1817-1827 (2002).
109. Loeb, K. R. et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8, 35-47 (2005).
110. Smith, A. P. et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 25, 7245-7259 (2006).
111. Fbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene 26, 6948-6953 (2007).
112. Issaeva, N. et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl Acad. Sci. USA 100, 13303-13307 (2003).
113. Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104 (2002).
114. Grabher, C., von Boehmer, H. & Look, A. T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Rev. Cancer 6, 347-359 (2006).
115. Schulman, B. A. et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 408, 381-386 (2000).
116. Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F box-Skp2 SCF ubiquitin ligase complex. Nature 416, 703-709 (2002).
117. Jin, J. et al. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18, 2573-2580 (2004).
118. Willems, A. R., Schwab, M. & Tyers, M. A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim. Biophys. Acta 1695, 133-170 (2004). A comprehensive review on ubiquitin ligases.
119. Cdc4 ubiquitin ligase regulates calcineurin signaling through degradation of phosphorylated Rcn1, an inhibitor of calcineurin. Proc. Natl Acad. Sci. USA 104, 17418-17423 (2007).